Christopher Hill
Analyst · Stifel. Please go ahead
Thanks, Larry. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls specifically excluded the impact of any FX gains or losses and assumed an effective tax rate of 20%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. So now looking at the income statement. Revenue was $128.2 million in the fourth quarter, up 2% compared to the prior quarter and flat year-over-year. Activity associated with international upstream projects and product sales to international clients continues to expand. However, the growth was partially offset by lower level of product sales in the US land market. Additionally, laboratory services associated with crude assay analysis have been adversely impacted in certain regions due to the ongoing conflict in Ukraine, Russia and the Middle East causing disruptions to the trading and maritime movement of crude oil. Of this revenue, service revenue, which is more international, was $94.7 million for the quarter, up 2% sequentially and up 6% from last year. During the quarter, committed work volumes for traditional Reservoir Rock and Fluid Analysis as well as carbon capture and storage projects continue to build across our global laboratory network. Additionally, we experienced nice sequential growth in revenue from our well and completion diagnostic services associated with both international and Gulf of Mexico projects. However, sequential growth in service revenue was partially offset by lower levels of crude assay work due to the disruptions caused by the ongoing conflicts previously mentioned. For the full year of 2023, service revenue of $371.9 million was up over 7% compared to $347 million in 2022. As Larry mentioned earlier, client activity levels associated with international upstream projects improved nicely in 2023 and are expected to continue building throughout 2024. Product sales, which is more equally tied to US and international activity were $33.5 million for the quarter up 3% sequentially, but down 13% from the same quarter in 2022. Product sales to international markets were up 18% sequentially with strong sales during the quarter and a couple of sales that were originally scheduled for the third quarter, which were delivered in the fourth quarter. Growth in international product sales was partially offset by the decrease in US onshore activity and associated US product sales during the quarter. For the full year of 2023, product sales of $137.9 million were down a little over 3% from $142.8 million in 2022 primarily associated with activity decline in the US onshore market, where the onshore rig count in the US decreased by approximately 20%. Moving on to cost of services, ex items for the quarter was approximately 75% of service revenue comparable to the prior quarter and an improvement of 78% compared to the fourth quarter of 2022. Over 80% of the company's personnel support our services business and the company implemented its annual merit cycle October 1, which increased personnel costs for the fourth quarter. Additionally, the service side of our business has been more impacted by the geopolitical conflicts and disruptions with the associated crude assay laboratory services. However, Reservoir Rock and Fluid Analytical Programs associated with international upstream projects have not been impacted by these conflicts and continue to build. Outside of the temporary disruptions, we continue to see improvements in absorption of costs and utilization of our global laboratory network and anticipate additional improvement with continuing growth in service revenue. For the full year of 2023, cost of services ex items was approximately 76% of service revenue, an improvement from 79% last year. Cost of sales ex items in the fourth quarter was 91% of revenue compared to 85% in the prior quarter. The increase this quarter is primarily due to reduced manufacturing efficiencies associated with lower US onshore sales. The company anticipates the US onshore activity levels will remain at similar levels for 2024. As such, we are finalizing plans to improve profitability and manufacturing efficiencies. G&A ex items for the quarter was $8.7 million, a decrease from the prior quarter, which was $9.5 million. Full year 2023 G&A ex items was $36.6 million compared to $39.3 million in the full year of 2022. For 2024, we expect G&A to be approximately $40 million to $44 million. Depreciation and amortization for the quarter was $3.9 million, flat compared to the last quarter. EBIT ex items for the quarter was $15 million, down $1 million from last quarter, yielding an EBIT margin of 12%. Year-over-year EBIT ex items for the fourth quarter was relatively flat to last year. Our operating income for the fourth quarter on a GAAP basis was $14.6 million. Full year 2023 EBIT ex items was $61.2 million, up 36% from $44.8 million in 2022. On a GAAP basis, EBIT was $54.6 million for 2023 and $41.5 million in 2022. Interest expense of $3.6 million increased this quarter when compared to $3.1 million in the prior quarter. Despite reducing our debt by $15 million during the quarter as discussed during the last call, $75 million in senior notes matured on September 30th, 2023, which carried a fixed interest rate of 4.1%. We used the borrowing capacity under our credit facility to partially fund the maturity of these notes. The credit facility has a variable interest rate and currently, the borrowing rate under the facility is approximately 8%. As such, our interest expense increased for the fourth quarter of 2023. Income tax expense and an effective tax rate of 20% and ex items was $2.3 million for the quarter. On a GAAP basis, tax expense was $4.3 million for the quarter, which was primarily impacted by an additional adjustment of deferred income taxes associated with the re-domestication of our parent company from the Netherlands to the US. For the full year, income tax expense on a GAAP basis was a small benefit, primarily due to the tax benefit of $11.6 million associated with the re-domestication transaction. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe and the impact of items discrete to each quarter. However, we continue to project the company's effective tax rate to be approximately 20%. Net income ex items for the quarter was $8.9 million, down from $10.3 million in the prior quarter and $9.3 million from the same quarter last year. On a GAAP basis, we recorded net income of $6.5 million for the quarter. For the full year 2023, net income ex items was $37.8 million, up 42% from $26.6 million last year and GAAP net income for the full year 2023 was $40.9 million. Earnings per diluted share ex items was $0.19 for the quarter, down from $0.22 in the prior quarter and $0.20 from the same quarter last year. On a GAAP basis, earnings per diluted share was $0.14 for the quarter. For the full year 2023, earnings per diluted share ex items was $0.80, up 40% from last year. And on a GAAP basis, full year 2023 was $0.86. Turning to the balance sheet. Receivables were $109.4 million, an increase of approximately $5.3 million from the prior quarter. Our DSOs for the fourth quarter were at 71 days and comparable to the prior quarter. Inventory was $71.7 million at the end of this quarter, a decrease of approximately $3.4 million from last quarter end. Inventory turns for the quarter improved to 1.7 from 1.5 in the last quarter. And with a focused effort for improvement in our inventory management, we anticipate inventory turns will gradually improve and inventory levels to decline as we progress into 2024. On the liability side of the balance sheet, our long-term debt was $166 million at December 31, 2023, a reduction of $15 million this quarter. Considering cash of $15.1 million, net debt was $150.9 million, down from $164.4 million at the end of the prior quarter. We remain focused on reducing debt and improving the leverage ratio of the company. Free cash flow generated in the quarter -- during the quarter was primarily used to reduce debt. Our leverage ratio improved considerably to 1.76 from 1.92 in the prior quarter. Our debt is currently comprised of our senior notes at $110 million and $56 million outstanding under our bank credit facility. Our credit facility has a borrowing capacity of $135 million, of which approximately $69 million was still available at December 31. Still announcing the company's commitment and focus on reducing debt in the fourth quarter from -- since announcing from the fourth quarter of 2019, we have reduced our net debt by almost 50%. The company will continue applying free cash towards reducing debt until we reach our target ratio of 1.5 times or lower. Looking at cash flow for the fourth quarter of 2023, cash flow from operating activities was $19.4 million and after paying for $2.7 million of CapEx during the quarter, our free cash flow was $16.7 million. The fourth quarter's cash flow includes the receipt of a tax refund of approximately $7 million. However, it's also a reflection of improved profitability and inventory management. Looking ahead to 2024, we are forecasting cash from operations to improve compared to 2023, and we will continue to manage investment in working capital during a period of growth. Additionally, we expect CapEx to remain aligned with activity levels. And for the full year of 2024, we expect capital expenditures to be in the range of $14 million to $16 million. Projected CapEx for 2024 also includes approximately $2 million associated with consolidation of some operational facilities in Houston, which will reduce long-term operating costs once complete. Core will continue its strict capital discipline and asset-light business model with capital expenditures primarily targeted at growth opportunities. Core Lab's operational leverage continues to provide the ability to grow revenue and profitability with minimal capital requirements. Capital expenditures have historically ranged from 2% to 4% of revenue even during periods of significant growth. That same level of laboratory infrastructure, intellectual property and leverage exists in the business today. We believe evaluating a company's ability to generate free cash flow and free cash flow yield is an important metric for shareholders when comparing and projecting company's financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen for an update on our guidance and outlook.